In order to assess the chemo-sensitizer ability of prexasertib, different experiments combining the Chk1/Chk2 inhibitor with different compounds routinely used in the clinic management of ALL were performed. This evidence concerns the gene CHEK2 and acute lymphoblastic leukemia.